We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Optibiotix Health Plc | OPTI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -1.43% | 17.25 | 15:00:22 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.50 | 17.25 | 17.50 | 17.25 | 17.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 18/12/2024 19:54 by putinaire How's the OPTI study at Hull Uni going? |
Posted at 10/12/2024 14:34 by putinaire Big news? LolPutinaire - 09 Dec 2024 - 10:10:33 - 67677 of 67686 OptiBiotix - The uncensored thread - OPTI Well the maker here knows that a false market is required to keep it up above 15.5/15 range. But i think that's illegal so it wont be contemplated of course. Same as it was not contemplated 3 weeks ago to get some dump liquidity going. Sub 15 is Armageddon |
Posted at 07/12/2024 08:53 by pj 1 If they do need funds hence the selling in Skin then SOH has some serious explaining to doFrom the Palcing in March, just £1.3m! OptiBiotix Health PLC 25 March 2024 OptiBiotix Health plc ("OptiBiotix" or the "Company") Placing, Subscription and Director Dealing OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces it has raised in aggregate £1,350,500 through the issue of 6,752,500 new ordinary shares of 2 pence each in the Company ("Fundraise Shares") at a price of 20 pence per share ("Issue Price") (together, the "Fundraise") handled by Peterhouse Capital Limited. The Fundraise comprises a placing of 6,627,500 new ordinary shares at the Issue Price, raising gross proceeds of £1,325,500 (the "Placing") and a subscription for 125,000 new ordinary shares at the Issue Price, raising gross proceeds of £25,000, by Graham Myers, a director of the Company (the "Subscription"). Following the Subscription, Graham Myers will be interested in 125,000 ordinary shares in the Company, representing 0.13 per cent. of the Company's issued share capital following Admission (as defined below). The net proceeds of the Fundraise will be utilised to invest in driving sales growth by:- 1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales; 2. increased presence of the Company's stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners; 3. investing in marketing the Company's products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and 4. launch its second generation SweetBiotix and MicroBiome Modulator products. The word co-invest was used, so its not for Morepen, hes al;ready raised for sweetbiotox but delivered nothing so those funds must still be here. So, key question, IF it is OPTI reducing then what the hell for? |
Posted at 03/12/2024 07:22 by kreature RNS ‘ This is the first time OptiBiotix has co-invested in marketing with a partner on this scale and includes a significant and comprehensive marketing plan and budget of £1.5m+.’Um……. and who pays that ? Uncapped ‘+’ ‘ Revenues will be both generated through raw material sales of SlimBiome® to our contract manufacturer KAG Industries (RNS: 30 April 2024) and as a second larger revenue stream for the finished product sold direct to Morepen.’ Why would KAG buy the raw materials ? And then I suppose revenue from product sold to Morepen will be less manufacturing and uncapped marketing costs ? What are the chances of any cash being sent from Morepen to Opti ? |
Posted at 06/11/2024 19:55 by putinaire 'Well this is good news. More in hope that expectation I texted him asking when the launch in India of the Dr Morepen jv was due. This is the deal that is planned to deliver GP of £5-6 million a year to Optibiotix (OPTI) within five years'..........ummm kreature6 Nov '24 - 19:37 - 67474 of 67481 0 0 0 Good choice ? ................ New Delhi: Capital markets regulator SEBI on Tuesday barred Morepen Laboratories from the capital markets for one year for making misleading disclosure about the issuance of global depository receipts (GDRs). |
Posted at 30/10/2024 14:17 by putinaire I reckon OPTI spent more on getting advice in the past 8 weeks, than they did on marketing in 10 years. Well, shareholders. Not opti |
Posted at 26/10/2024 18:44 by putinaire 2017OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans to launch products containing its cholesterol reducing strain (LPLDL®) at the Vitafoods Europe Trade Show ("Vitafoods") in Geneva on the 9-11 May 2017. The trade show provides opportunities to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. The event is viewed as one of the world's leading trade fairs for the food and drinks industry ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL® strain in Europe with a view to maximising the financial return for both parties. .............. OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherhe ............... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year supply agreement with Galenicum Special Ingredients, S.L ("Galenicum") to commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL®. The agreement grants Galenicum a non-exclusive license to commercialise Cardiocare™, a nutritional supplement containing OptiBiotix's LPLDL® in Spain, Chile, Peru and the Middle East with the aim of maximising the financial return for both parties. .............. 2018 OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a production and commercialisation agreement with Fine Foods & Pharmaceuticals N.T.M. S.p.A ("Fine Foods"). The agreement grants Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties. ............ OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into license agreement with ALFASIGMA S.p.A. ("ALFASIGMA") to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy. ......... |
Posted at 24/10/2024 09:11 by kreature I did say it was prob just a massive oversight. Easy to do with such a round number I guess….Just got to hand the shares back somehow now I suppose ? Or unsell them? DunnoRNS, ……. OptiBiotix Health plc ("OptiBiotix" or the "Company" or "the Group") Total Voting Rights OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM. |
Posted at 24/10/2024 08:41 by putinaire OPTI RNS recently, included advice to PBX[... OptiBiotix advised of its recent successful fundraise of £1.35m by the Company and identified lack of market communication by Mr Andersen as the main reason for the failed PBX fundraise. OptiBiotix requested that PBX increase its news flow to potentially support the share price and build positive investor sentiment ...] Did they advise SBTX yesterday too? So more could be sold? |
Posted at 20/8/2024 09:08 by easybrent From lse chat:Looks like poor financial development in H1. In todays RNS they write “Excluding milestone payments received in H2 2023, reported revenues in H1 2024 will be ahead of H2 2023.” Lets go back and see where reported revenue were: H2 2023 £293k H1 2023 £351k H2 2022 £338k The other point to look at is what the milestone payments was in H2, OptiBiotix doesn’t give the precise number but in the 19 Jul 2023 RNS the company wrote “They are paying OptiBiotix a six-figure annual milestone in H2 every year during scale up plus”. If we assume that this milestone payment is £100k which would represent a six-figure milestone payment as per OPTI RNS. Reported revenue for H2 2023 was £293k and excluding the milestone payment it would be £193k. OptiBiotix is writing that revenue in H1 2024 is ahead of this figure, I guess fair estimate is that its in the range of £200-250k. If this is the case H1 2024 revenue is really poor, especially compared to H1 2023 revenue which was £338k. This is supposed to be growth company, but it seems to be shrinking, while the company continues to cherry pick positive development. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
